These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 12606603

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists.
    Walczyński K, Zuiderveld OP, Timmerman H.
    Eur J Med Chem; 2005 Jan; 40(1):15-23. PubMed ID: 15642406
    [Abstract] [Full Text] [Related]

  • 43. [Identification of a HEK-293 cell line containing stably-transfected H3R gene and screening for novel non-imidazole histamine H3 receptor antagonists].
    He P, Tan L, Hu W, Dai H, Hu Y, Chen Z.
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 May; 42(3):276-82. PubMed ID: 23801615
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. High constitutive activity of native H3 receptors regulates histamine neurons in brain.
    Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, Arrang JM.
    Nature; 2000 Dec 14; 408(6814):860-4. PubMed ID: 11130725
    [Abstract] [Full Text] [Related]

  • 47. Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.
    Lovenberg TW, Pyati J, Chang H, Wilson SJ, Erlander MG.
    J Pharmacol Exp Ther; 2000 Jun 14; 293(3):771-8. PubMed ID: 10869375
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Differential effects of the 5-hydroxytryptamine (5-HT)1A receptor inverse agonists Rec 27/0224 and Rec 27/0074 on electrophysiological responses to 5-HT1A receptor activation in rat dorsal raphe nucleus and hippocampus in vitro.
    Corradetti R, Mlinar B, Falsini C, Pugliese AM, Cilia A, Destefani C, Testa R.
    J Pharmacol Exp Ther; 2005 Oct 14; 315(1):109-17. PubMed ID: 15951403
    [Abstract] [Full Text] [Related]

  • 51. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.
    Tedford CE, Yates SL, Pawlowski GP, Nalwalk JW, Hough LB, Khan MA, Phillips JG, Durant GJ, Frederickson RC.
    J Pharmacol Exp Ther; 1995 Nov 14; 275(2):598-604. PubMed ID: 7473144
    [Abstract] [Full Text] [Related]

  • 52. A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists.
    Ganellin CR, Fkyerat A, Bang-Andersen B, Athmani S, Tertiuk W, Garbarg M, Ligneau X, Schwartz JC.
    J Med Chem; 1996 Sep 13; 39(19):3806-13. PubMed ID: 8809168
    [Abstract] [Full Text] [Related]

  • 53. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
    Sadek B, Elz S, Pertz HH, Stark H, Schunack W.
    Inflamm Res; 2004 Aug 13; 53 Suppl 2():S109-15. PubMed ID: 15338060
    [Abstract] [Full Text] [Related]

  • 54. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
    Mezzomo K, Cumming P, Minuzzi L.
    Eur J Pharmacol; 2007 Jun 14; 564(1-3):75-9. PubMed ID: 17350614
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Novel histamine H(3)-receptor antagonists and partial agonists with a non-aminergic structure.
    Nickel T, Bauer U, Schlicker E, Kathmann M, Göthert M, Sasse A, Stark H, Schunack W.
    Br J Pharmacol; 2001 Apr 14; 132(8):1665-72. PubMed ID: 11309237
    [Abstract] [Full Text] [Related]

  • 57. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC.
    Synapse; 2006 Dec 15; 60(8):599-608. PubMed ID: 17001660
    [Abstract] [Full Text] [Related]

  • 58. Histamine H3 and H4 receptors as novel drug targets.
    Tiligada E, Zampeli E, Sander K, Stark H.
    Expert Opin Investig Drugs; 2009 Oct 15; 18(10):1519-31. PubMed ID: 19758107
    [Abstract] [Full Text] [Related]

  • 59. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M, Kazuta Y, Hayashi H, Yamada S, Matsuda A, Shuto S.
    J Med Chem; 2006 Sep 07; 49(18):5587-96. PubMed ID: 16942032
    [Abstract] [Full Text] [Related]

  • 60. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor.
    Stark H, Purand K, Hüls A, Ligneau X, Garbarg M, Schwartz JC, Schunack W.
    J Med Chem; 1996 Mar 15; 39(6):1220-6. PubMed ID: 8632428
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.